Pre-eclampsia – European Clinical Trials Information Network

Acetylsalicylic Acid for Preventing Preeclampsia in Pregnant Women

Wed, 13 May 2026 05:05:03 +0000

This clinical trial is studying preeclampsia, a pregnancy condition that can cause high blood pressure and other problems for the mother and baby. The treatment being used is acetylsalicylic acid, also known as aspirin. The purpose of the study is to find out whether stopping aspirin between weeks 24 and 26 of pregnancy works as well as continuing it until week 36 for preventing preterm preeclampsia.

In the study, pregnant participants will take aspirin by mouth during pregnancy, and then one group will stop it earlier while the other group will continue it longer. The study will then compare the two approaches to see whether stopping aspirin earlier is still safe for the mother and baby and whether it may lower the risk of bleeding in the mother.

Study on Pravastatin for Pregnant Patients with Preeclampsia or Intrauterine Growth Restriction

Wed, 29 Apr 2026 15:05:54 +0000

This clinical trial is focused on studying two pregnancy-related conditions: preeclampsia and intrauterine growth restriction (IUGR). Preeclampsia is a condition characterized by high blood pressure during pregnancy, which can lead to serious complications for both the mother and baby. Intrauterine growth restriction refers to a condition where the baby grows slower than expected in the womb. The study will use a medication called Pravastatin, which is commonly used to lower cholesterol, to see if it can help manage these conditions during pregnancy.

The purpose of the study is to determine if taking 40 mg of Pravastatin daily can help prolong pregnancy in women diagnosed with severe early-onset preeclampsia or IUGR between 24 and 29 weeks of gestation. Participants in the study will be randomly assigned to receive either Pravastatin or a placebo, which looks like the medication but does not contain the active ingredient. The study will monitor the duration of pregnancy from the time of inclusion until delivery.

Participants will take the medication orally in the form of a tablet. The study aims to provide insights into whether Pravastatin can be an effective treatment strategy for managing these conditions and potentially improving outcomes for both mothers and their babies. The trial is expected to continue until the end of 2027, with recruitment starting in 2025.

Study on Low Dose Acetylsalicylic Acid to Prevent Preeclampsia in Pregnant Women After Frozen Embryo Transfer

Wed, 29 Apr 2026 14:59:35 +0000

This clinical trial is focused on studying the condition known as preeclampsia, which can occur during pregnancy and is characterized by high blood pressure and potential damage to other organs, often the liver and kidneys. The study is investigating the use of a medication called acetylsalicylic acid, commonly known as aspirin, in a low dose of 160 mg. This medication is being tested as a preventive treatment for preeclampsia in pregnant women who have undergone a procedure called frozen embryo transfer, which is a part of some fertility treatments.

The purpose of the study is to determine if taking low-dose acetylsalicylic acid can reduce the occurrence of preeclampsia in these women. Participants in the study will be randomly assigned to either receive the medication or not receive any treatment, which is known as a placebo group. The study will monitor the health of the participants throughout their pregnancy to see how many women in each group develop preeclampsia.

The study will take place over a period of time, with participants being followed from the early stages of their pregnancy. The goal is to gather enough information to understand whether the use of acetylsalicylic acid can effectively prevent preeclampsia in women who have had a frozen embryo transfer. This research could potentially lead to new guidelines for preventing this condition in similar cases in the future.

Study of Metformin to Extend Pregnancy Duration in Women with Preterm Preeclampsia

Wed, 29 Apr 2026 14:59:09 +0000

This clinical trial investigates the use of metformin in pregnant individuals with preterm preeclampsia. Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to organ systems, particularly the liver and kidneys. When it occurs before 32 weeks of pregnancy, it is called preterm preeclampsia. The study also includes patients with HELLP syndrome, a severe form of preeclampsia that affects the blood and liver, and other hypertensive disorders of pregnancy.

The study aims to determine if metformin can help extend pregnancy duration in individuals with preterm preeclampsia. Participants will receive either metformin tablets or placebo. The medication will be given as film-coated tablets for oral use, with doses up to 3000 mg per day for up to 98 days.

The treatment involves taking the study medication daily until delivery or until it becomes necessary to end the pregnancy for medical reasons. The study will monitor both the mother’s health and the baby’s development throughout the treatment period. The medication will be provided in a modified form (overencapsulated) to ensure that neither the participant nor the healthcare provider knows whether they are receiving metformin or placebo.

Study on Aspirin for Preventing Preeclampsia in First-Time Pregnant Women Using Assisted Reproductive Technology

Wed, 29 Apr 2026 14:25:09 +0000

This clinical trial is focused on studying preeclampsia, a condition that can occur during pregnancy, characterized by high blood pressure and potential damage to other organs, often the liver and kidneys. The study is investigating the use of acetylsalicylic acid, commonly known as aspirin, as a preventive treatment. Aspirin is being tested in a daily dose of 150 milligrams, taken orally in the form of a hard capsule. The trial aims to determine if aspirin can help prevent preterm preeclampsia, which is when the condition develops before 37 weeks of pregnancy, in women who are pregnant for the first time after using assisted reproductive technology, such as in vitro fertilization.

The purpose of the study is to evaluate the effect of aspirin compared to a placebo in preventing preterm preeclampsia. Participants will begin taking the medication between 9 and 14 weeks of pregnancy and continue until the 26th week. Throughout the study, various outcomes will be monitored, including the occurrence of preeclampsia, preterm birth, cesarean delivery, and other pregnancy-related complications. The study will also track the health of the newborn, including birth weight and any complications that may arise after birth.

Participants will be asked to adhere to the treatment regimen, and their adherence will be monitored by counting the pills at each visit and using a diary or application. The study will also consider the cost-effectiveness of the treatment, looking at the costs associated with hospitalizations, consultations, and other medical expenses. The trial is expected to conclude by the end of 2026, with recruitment having started in early 2023.

Study on Aspirin for Preventing Preeclampsia in Twin Pregnancies

Wed, 29 Apr 2026 14:24:43 +0000

This clinical trial is focused on studying preeclampsia, a condition that can occur during pregnancy, characterized by high blood pressure and potential damage to other organs, often the liver and kidneys. The study is specifically looking at twin pregnancies. The treatment being tested is Aspirin 75mg Gastro-resistant Tablets, which contains the active ingredient acetylsalicylic acid. This medication is being compared to a placebo to see if it can help prevent preeclampsia in women expecting twins.

The purpose of the study is to determine if taking a low dose of aspirin can reduce the chances of developing preeclampsia before 37 weeks of pregnancy. Participants in the study will be randomly assigned to receive either the aspirin or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the aspirin and who is receiving the placebo, to ensure unbiased results.

Throughout the study, participants will take the assigned tablets orally. The trial will monitor the health of the participants and their pregnancies to assess the effectiveness of aspirin in preventing preeclampsia. The study aims to provide valuable information on whether aspirin can be a helpful preventive treatment for preeclampsia in twin pregnancies.

Study on Metformin for Prolonging Pregnancy in Women with Preterm Preeclampsia

Wed, 29 Apr 2026 14:24:14 +0000

This clinical trial is focused on studying preeclampsia, a condition that can occur during pregnancy, characterized by high blood pressure and signs of damage to other organ systems. The study is investigating whether a medication called metformin, specifically in the form of Glucophage SR 500mg prolonged release tablet, can help prolong pregnancy in women diagnosed with preterm preeclampsia. Preterm preeclampsia refers to the condition occurring before the pregnancy reaches full term, which is typically before 37 weeks of gestation.

The purpose of the study is to determine if taking 3 grams of metformin daily can extend the duration of pregnancy in women who are managing preterm preeclampsia with expectant management, which means closely monitoring the condition without immediate delivery. Participants in the study will be randomly assigned to receive either the metformin treatment or a placebo, which is a substance with no active medication. The study will follow the participants from the time they are enrolled until they give birth, to see if the treatment helps in prolonging the pregnancy.

Throughout the study, researchers will also look at other factors such as the length of time newborns stay in neonatal care and the birth weight of the babies. The goal is to gather information that could help improve outcomes for both mothers and their babies when dealing with preterm preeclampsia. This study is expected to continue until March 2028, providing valuable insights into the potential benefits of using metformin in managing this condition.

Study of Acetylsalicylic Acid (Aspirin) 150 mg for Prevention of Complications in Pregnant Women with Chronic Hypertension

Wed, 29 Apr 2026 14:22:59 +0000

This study focuses on pregnant women with chronic hypertension, a condition where blood pressure remains consistently high. The research examines how acetylsalicylic acid (also known as aspirin) affects pregnancy-related complications including pre-eclampsia (a serious condition causing high blood pressure during pregnancy), fetal growth restriction (when a baby doesn’t grow properly in the womb), and other pregnancy-related blood pressure problems.

The study compares the effects of taking 150 mg of acetylsalicylic acid daily with a placebo to prevent serious complications that could affect both mother and baby. These complications include pre-eclampsia, separation of the placenta from the womb, reduced baby growth, early delivery, and other serious health issues for both mother and baby.

Participants in this study will receive either acetylsalicylic acid in the form of gastro-resistant tablets (tablets that dissolve in the intestine rather than the stomach) or identical-looking placebo tablets. The treatment continues for 6 months during pregnancy. The study is designed so that neither the pregnant women nor their healthcare providers know which treatment they are receiving during the study period.